RxDoctor Payments Data

Michael Beckham, MD

Internal Medicine · Hermitage, TNNPI 1053303248

Payments from drug & device makers

$8,829in general payments, 2019–2025

Across 525 payments — averaging $16.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • AstraZeneca$1K
  • GSK$860
  • Amgen$841
  • Lilly USA, LLC$531
  • Pfizer$505
  • plus $3K from 36 others

What the payments were for

  • Food & beverage$8,71499%
  • Education$1151%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,829 in reported general payments places this provider in the 90th percentile of 2,216 internal medicine providers in Tennessee.

See all internal medicine providers in Tennessee

Medicare billing

Part B allowed, 2024
$46,769
Medicare patients
97
Services billed
1,192

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban26$31,545
FarxigaDapagliflozin Propanediol19$25,806
OzempicSemaglutide15$23,956
Trelegy ElliptaFluticasone/Umeclidin/Vilanter22$20,757
Nurtec OdtRimegepant Sulfate11$20,647
MyrbetriqMirabegron25$20,158
Rosuvastatin Calcium229$3,604
Atorvastatin Calcium184$2,874
Allopurinol26$2,660
Celecoxib24$2,191
Diltiazem 24hr Er (Cd)Diltiazem Hcl34$2,135
Ezetimibe49$1,828
Potassium Chloride48$1,794
PaxlovidNirmatrelvir/Ritonavir18$1,429
Pantoprazole Sodium66$1,338

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Nurtec Odt, Paxlovid$505$53,62255 claims
AstraZenecaFarxiga$1,271$25,80619 claims
Novo NordiskOzempic$1,659$23,95615 claims
GSKTrelegy Ellipta$860$20,75722 claims
Astellas Pharma US IncMyrbetriq$378$20,15825 claims
AbbVieSynthroid$472$74520 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,216 internal medicine providers in Tennessee.

Other internal medicine in Hermitage

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →